Formulary

There are promising developments in the pipeline for patients with treatment-resistant depression.

Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.

Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.

Drug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.

Like any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications-just a year after Medicare Part D extended its coverage to include them in 2012-has some wondering why so many of these drugs are being prescribed.

AMCP 2016 conference presenters from MedImpact outline their High-Cost Generic program that moves members to less-expensive, clinically relevant drug alternatives.

IMS Health expert predicts future drug spending trends and ways to curb rising costs at the AMCP 2016 conference.

At the AMCP16 conference, Managed Healthcare Executive invited some of the nation’s leading pharmacy and managed care experts to join us to discuss some of the most critical managed care pharmacy challenges facing the industry.

PCSK9 inhibitor benefits patients with statin intolerance

The approaches reflect a growing number of initiatives meant to tie drug prices to value. Find out more.

PBMs, insurers use cautious approach when managing these cholesterol-lowering drugs.

Four new drugs and a biosimilar should be on your radar.

When it comes to managing rheumatoid arthritis drugs, cost comes in various sizes and shapes.

An oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved.

A new Urban Institute study looks at the availability of antidepressants in marketplace insurance plans.

FDA’s approval of Vertex Pharmaceutical’s groundbreaking lumacaftor/ivacaftor (Orkambi) for cystic fibrosis (CF) is the first drug to treat the underlying cause of CF in people ages 12 and older with two copies of the F508del mutation.

In this commentary, three pharmacy experts explain why they believe the 340B Drug Program is a needed safety net for safety net hospitals.

The number of deaths from prescription pain relievers dropped 5% in 2012, and new tools are helping in the fight against opioid abuse.

Increasing unnecessary regulations on drug plans could inflict higher costs on the 220 million Americans who get their medications through a managed drug plan, according to a new report.

Controversy surrounds the 340B Drug Discount Program, and many industry leaders agree that the healthcare law plays a large part.

Breakthrough Therapy Designation given to daclatasvir and asunaprevir

PBMs are moving products to non-covered status

Will ACA exchanges earn 90% satisfaction ratings someday?

Drugs are free of interferon and aim to shorten treatment time

Test patient response with initial 14 day fill